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Summary
Autocrine Wnt signaling in the mouse mammary tumor virus model was the first identified mechanism of canonical pathway
activation in cancer. In search of this transformation mechanism in human cancer cells, we identified breast and ovarian
tumor lines with upregulation of the uncomplexed transcriptionally active form of -catenin without mutations afflicting
downstream components. Extracellular Wnt antagonists FRP1 and DKK1 caused a dramatic downregulation of -catenin
levels in these tumor cells associated with alteration of biological properties and increased expression of epithelial differenti-
ation markers. Colorectal carcinoma cells with knockout of the mutant -catenin allele retained upregulated -catenin
levels, which also could be inhibited by these Wnt antagonists. Together, these findings establish the involvement of
autocrine Wnt signaling in human cancer cells.
Introduction initial discovery of a Wnt autocrine transforming mechanism in
the mouse model more than two decades ago, evidence for
this mechanism in human cancer is lacking.Wnt signaling plays a critical role in cell fate determination and
tissue development (Nusse and Varmus, 1992; Cadigan and Extracellular inhibitors that function to fine-tune the spatial
and temporal patterns of Wnt activity and act at the cell surfaceNusse, 1997). Certain members of this family of secreted glyco-
proteins interact with coreceptors, Frizzled and LRP5/6, leading to inhibit Wnt signaling through its receptors have recently been
discovered (Kawano and Kypta, 2003). One group of Wnt antag-to inhibition of-catenin phosphorylation by the serine threonine
kinase, glycogen synthase kinase- (GSK-3), within a large onists is the secreted Frizzled-related proteins (FRPs), which
share sequence similarity with the Frizzled receptor CRD (cys-cytoplasmic complex including Dishevelled (Dsh), APC, and
Axin (Giles et al., 2003). Inhibition of -catenin phosphorylation teine rich domain), but lack the transmembrane and intracellular
domains (Leyns et al., 1997; Wang et al., 1997; Finch et al.,impairs its degradation by the ubiquitin/proteosome pathway,
resulting in accumulation of the uncomplexed cytosolic mole- 1997). Through its CRD, FRP exhibits the ability to bind Wnt,
form dimers, and heterodimerize with Frizzled (Leyns et al.,cule. Uncomplexed -catenin then translocates to the nucleus,
where it interacts with TCF/LEF and activates target genes (Giles 1997; Wang et al., 1997; Rattner et al., 1997; Lin et al., 1997;
Bafico et al., 1999). Thus, FRP may act not only to sequesteret al., 2003). Accumulating evidence indicates that signaling
through the Wnt canonical pathway regulates the differentiation Wnts but also to inhibit Wnt signaling via formation of nonfunc-
tional complexes with the Frizzled receptor. Another potent Wntof adult stem cells in the epithelium of colon (van de Wetering
et al., 2002a) and skin (Alonso and Fuchs, 2003), as well as in antagonist, designated Dickkopf-1 (DKK1), is the prototype of
a family of secreted proteins structurally unrelated to Wnt ormuscle (Polesskaya et al., 2003) and hematopoietic cells (Reya
et al., 2003). Constitutively activated Wnt signaling has also Frizzled (Glinka et al., 1998; Fedi et al., 1999). DKK1 binds
the Wnt coreceptor LRP6 and causes its endocytosis throughbeen shown to be causally involved in cancer (Polakis, 2000).
Wnts were initially identified as a consequence of their transcrip- formation of a ternary complex with the transmembrane protein
Kremen (Mao et al., 2001, 2002; Bafico et al., 2001; Semenovtional activation by mouse mammary tumor virus promoter in-
sertion, which initiates mammary tumor formation (Nusse and et al., 2001). Since LRP6 has been shown to activate only the
Wnt/-catenin pathway (Pinson et al., 2000; Wehrli et al., 2000),Varmus, 1992). Later studies established that genetic alterations
afflicting APC and -catenin, leading to increased uncomplexed the interaction of DKK1 with LRP6 establishes DKK1 as a spe-
cific antagonist of canonical Wnt signaling. The availability of-catenin levels, occur very commonly in human colon and
other cancers (Polakis, 2000; Giles et al., 2003). Despite the specific antagonists that inhibit Wnt signaling at the level of
S I G N I F I C A N C E
The highly conserved Wnt canonical signaling pathway plays a crucial role in normal development and in human tumorigenesis.
By use of specific antagonists that inhibit Wnt ligand signaling through its receptors, we identified a functional Wnt autocrine loop
in human breast and ovarian carcinoma cells. An increasing number of cancer therapeutic agents are being directed against
ligands or their cell surface receptors. Thus, autocrine Wnt signaling could provide a novel target for therapeutic intervention by
means of Wnt antagonists or other modalities that interfere with cell surface interactions of Wnts and their receptors.
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Table 1. Wnt signaling upregulation in human tumor cell lines.
Uncomplexed Inhibition by FRP














Figure 1. Wnt signaling upregulation in human tumor breast and ovarian Ovarian
cancer cell lines OVCAR3  
A: Analysis of uncomplexed and unphosphorylated -catenin in human A1847  
tumor cells. Around 1 mg of total cell lysates was subjected to the GST-E- A2780  ND
cadherin assay (Bafico et al., 1998). Following SDS-PAGE analysis, uncom- SKOV3  /
plexed -catenin was detected by an anti--catenin antibody (upper 44S  /
panel). An antiserum specific to dephosphorylated -catenin was utilized PAI  
to detect the uncomplexed unphosphorylated form of the protein (lower 26S  ND
panel). 53S  
B: RT-PCR analysis of Wnt ligands. RNA from each tumor cell line was reverse
Human tumor cell lines without detectable APC or -catenin mutationstranscribed and amplified with primers specific for each indicated Wnt
were analyzed for expression of uncomplexed -catenin as described ingene (see Experimental Procedures). Amplification was performed for 35
the Experimental Procedures. Relative levels were approximated based oncycles using the following profile: 94C for 30 s, optimized annealing temper-
comparison between different lines analyzed at the same time (see Figureature for 30 s, and 72C for 30 s. PCR products were resolved on a 2%
1). Inhibition by FRP1 and/or DKK1 was scored as positive based on theagarose gel and visualized by ethidium bromide staining.
results of at least three independent experiments. (ND not determined).
interaction with its surface receptors provided us with the means
to investigate whether Wnt autocrine signaling could be impli-
nists, which inhibit Wnt signaling at the level of ligand/receptorcated in human tumorigenesis.
interactions (Leyns et al., 1997; Wang et al., 1997; Bafico et al.,
1999, 2001; Mao et al., 2001; Semenov et al., 2001). As shownResults
in Figure 2A, addition of DKK1 to NIH3T3 cells stably expressing
Wnt-3a resulted in striking inhibition of upregulated -cateninIdentification of human breast and ovarian tumor cell
levels. In contrast, the same inhibitor had no effect on uncom-lines with constitutive Wnt pathway activation
plexed -catenin induced by exogenous -catenin expressedTo search for evidence of autocrine Wnt signaling in human
under the control of a tet regulatable promoter. Thus, we rea-tumors, we initially surveyed a panel of human breast and ovar-
soned that if a Wnt autocrine loop were functional in humanian tumor cell lines for increased levels of uncomplexed
tumor cells, FRP1 or DKK1 antagonists should cause specific-catenin. Several were identified as positive by this approach
inhibition of upregulated -catenin levels.(Figure 1A and Table 1). Activation of Wnt signaling specifically
increases the levels of N-terminally unphosphorylated -catenin, As shown in Figure 2B, exposure of MDAMB157 breast
which represents the transcriptionally active form of the protein tumor cells to increasing concentrations (0.5–10 nM) of purified
(van Noort et al., 2002; Staal et al., 2002). Analysis of the uncom- DKK1 (Bafico et al., 2001) led to a dose-dependent, marked
plexed -catenin pool with an antibody that specifically recog- reduction in the levels of uncomplexed -catenin (Figure 2B).
nizes the unphosphorylated form revealed that this pool in each Stable expression of FRP1 or DKK1 by retroviral-mediated
case contained the transcriptionally active form (Figure 1A). No transduction in MDAMB157 cells led to a dramatic reduction in
detectable oncogenic lesions in either -catenin or APC, the uncomplexed -catenin levels as well (Figure 2C). Inhibition of
most frequently altered cancer genes in this pathway (Polakis, constitutively upregulated -catenin was also observed with
2000; Bienz and Clevers, 2000), were found in any of these expression of FRP1 or DKK1 in several other breast and ovarian
-catenin upregulated tumor lines (data not shown), suggesting tumor cell lines, including MDAMB231, A1847, and PAI (Figure
a novel mechanism. In an effort to implicate Wnt autocrine
2D). The expression of Flag-tagged DKK1 and FRP1 proteinssignaling, we analyzed expression of representative Wnts by
in each of these cell lines was confirmed by immunoblot analy-RT-PCR using primers specific for each. Figure 1B shows that
sis. Wnt signaling activates TCF dependent transcription, whichthe Wnt ligands analyzed exhibited different patterns of expres-
can be monitored by reporters containing TCF-responsive ele-sion, and that the tumor cell lines containing upregulated
ments (Morin et al., 1997). DKK1 caused a striking reduction in-catenin expressed one or more of these Wnts.
the level of endogenous TCF-dependent signaling in a represen-
tative ovarian tumor cell line, PAI (Figure 2E). These findingsWnt antagonists identify autocrine Wnt signaling
further established that TCF-dependent transcription was con-in human tumor cells
stitutively activated in these tumor cells by an autocrine WntTo directly address the possibility of an autocrine signaling loop
in these cells, we took advantage of the FRP1 and DKK1 antago- mechanism. As summarized in Table 1, three of eleven breast
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Figure 2. FRP1 and DKK1 inhibition of autocrine Wnt signaling in human tumor cell lines
A: DKK1 acts at the level of ligand/receptor interactions. NIH3T3 cells expressing -catenin under the control of the Tet inducible promoter were grown for
4 days in the presence of different amounts of tetracycline (lanes 1 and 2: 1 g/ml; lanes 3 and 4: 7.5 ng/ml; lanes 5 and 6: 5 ng/ml). These cells as well
as Wnt expressing NIH3T3 cells were incubated with purified DKK1 (10 nM) (Bafico et al., 2001) and solubilized after 2 hr. 1 mg of total cell lysate was
subjected to the GST-E-cadherin binding assay, followed by SDS-PAGE and immunoblot analysis with the anti--catenin antibody.
B: Soluble DKK1 inhibits upregulated -catenin levels in MDAMB157 cells. Cultures were exposed to increasing concentrations of purified DKK1 for 2 hr,
solubilized, and analyzed for uncomplexed -catenin as described above.
C: MDAMB157 breast cancer cells were infected with either empty vector or FRP1-HA or DKK1-HA retroviruses and marker selected (top panel). Expression
of tagged FRP1 was assessed by immunoblot analysis of lysates with an anti-HA antibody (middle panel). The same antiserum was utilized to detect DKK1
in serum-free concentrated (5) conditioned media (lower panel).
D: Analysis of breast (MDAMB231) and ovarian (A1847, PAI) tumor cell lines for uncomplexed -catenin (upper panel) or HA-tagged FRP1 and DKK1 (lower
panel).
E: DKK1 inhibition of TCF-reporter transcriptional activity in PAI tumor cells. Cells were cotransfected with either TOP-Glow or Fop-Glow plasmids, and the
pCMV-RL plasmid encoding Renilla luciferase as an internal control for transfection efficiency. The values represent the mean (SD) of two independent
experiments, and the ratio of the activity obtained with the wild-type TOP-Glow plasmid to the activity observed with the mutant FOP-Glow plasmid is
shown.
tumor cell lines exhibited upregulated -catenin, which in each of these same siRNAs on PAI tumor cells and observed that
LRP6 but not LRP5 siRNA caused a marked inhibition in uncom-case was inhibited by FRP1 and/or DKK1. Two of eight ovarian
tumor cell lines demonstrated uncomplexed -catenin levels, plexed -catenin levels (Figure 3B, right panel). These results
provide strong evidence, independent of the use of Wnt antago-which were decreased in response to the antagonists. A high
level of upregulated -catenin was detected in 53S tumor cells nists, that constitutive Wnt signaling was due to an autocrine
loop in these human tumor cells, and implicated LRP6 as thebut showed no detectable response to the inhibitors, implying
a lesion in the canonical pathway other than an autocrine loop. specific Wnt canonical receptor involved.
Effects of Wnt autocrine signaling inhibitionInhibition of autocrine Wnt signaling by siRNA
directed against LRP6 on tumor cell phenotype
Exogenous expression of Wnts that signal through the canonicalIn an effort to independently confirm the existence of an auto-
crine Wnt signaling loop, we generated siRNAs specific for LRP5 pathway in mammalian cells causes acquisition of properties
associated with the transformed phenotype (Blasband et al., 1992;and LRP6, the Wnt coreceptors specific for the canonical path-
way (Pinson et al., 2000; Wehrli et al., 2000). As shown in Figure Wong et al., 1994; Shimizu et al., 1997; Bafico et al., 1998; Orford
et al., 1999). For example, stable expression of transforming3A, the exogenous expression of each LRP receptor in 293T
cells was specifically inhibited by the homologous but not the Wnts in responsive cells induces increased saturation density,
which can be specifically blocked by stable coexpression ofheterologous siRNA. When the same siRNAs were expressed in
293T cells treated with Wnt-3a conditioned media, we observed FRP1 or DKK1 (Bafico et al., 1998; Fedi et al., 1999). There is
also evidence that Wnt signaling can inhibit apoptosis (Chen etthat LRP6 siRNA caused a reduction in Wnt induced uncom-
plexed -catenin levels, while LRP5 siRNA had no detectable al., 2001; You et al., 2002; Longo et al., 2002). Having identified
human tumor cells with autocrine Wnt signaling, we analyzedeffect (Figure 3B, left panel). These results implied that canonical
signaling in response to Wnt-3a in these cells required endoge- the effects of FRP1 or DKK1 on these biological properties. As
shown in Figure 4A, MDAMB157 cells overexpressing FRP1 ornous LRP6. There was no effect of either siRNA on uncomplexed
-catenin levels in 293T cells expressing mutant-catenin under DKK1 exhibited decreased saturation density when compared
to vector-transduced parental cells. To confirm that the effectsthe same conditions (data not shown). We next tested the effects
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Figure 3. Effects of LRP5 and LRP6 siRNAs on Wnt signaling
A: Depletion of LRP5 and LRP6 by specific siRNAs. 19 nt siRNAs were generated against the extracellular domain of human LRP5 and LRP6 as described in
the Experimental Procedures. 293T cells were transiently transfected with 1 g of each siRNA construct along with 0.5 g of LRP5 or LRP6-FLAG. At 72 hr,
LRP5 protein levels were analyzed with an LRP5 polyclonal antibody (Orbigen), while LRP6 levels were detected utilizing an anti-FLAG antibody. The same
lysates were analyzed with an anti-tubulin antibody as a loading control.
B: Effects of LRP5 and LRP6 siRNAs on Wnt-3a-stimulated 293T cells or autocrine Wnt PAI human tumor cells. Left: subconfluent 293T cells were transiently
transfected with 2.5 g of each siRNA construct. After 72 hr, cells were treated for two hours with either control or Wnt-3a conditioned media and analyzed
for uncomplexed -catenin levels. Right: subconfluent PAI tumor cells were transiently transfected with 2.5 g of each siRNA and analyzed for uncomplexed
-catenin levels at 72 hr.
of FRP1 and DKK1 on MDAMB157 were through inhibition of of the inhibitors in these cells resulted in no detectable effect
on saturation density (data not shown).Wnt function, we infected the immortalized human mammary
epithelial cell line, AB589 (Stampfer and Bartley, 1985), which To assess the effects of Wnt inhibition by FRP1 or DKK1
on the response of MDAMB157 cells to apoptotic stimuli, weexhibited undetectable levels of uncomplexed-catenin, (Figure
1A) with either vector or FRP1 or DKK1 retroviruses. Expression exposed the cells to increasing concentrations of tert-butyl hy-
Figure 4. Functional effects of FRP1 and DKK1 inhibition of autocrine Wnt signaling in human breast tumor cells
A: FRP1 and DKK1 effects on saturation density. MDAMB157 cells exogenously expressing either vector control, FRP1, or DKK1 were transferred at 1.5  105
cells per well in 6-well plates. Cell counts were performed in duplicate at the indicated times, and values represent the mean of two independent
experiments.
B: Effects of FRP1 and DKK1 on apoptosis in response to an oxidative stress inducer. Subconfluent cultures of MDAMB157 or AB589 were treated with the
indicated amounts of tBh and subjected to FACS analysis at 24 hr as described in the Experimental Procedures. The values obtained are expressed as the
mean  SD of two independent experiments performed in duplicate.
C and D: FRP1 and DKK1 effects on Wnt target genes and differentiation markers. 40 g of total RNA extracted from MDAMB157 cells exogenously expressing
vector, FRP1, or DKK1 were resolved on a 1% agarose gel and transferred to a nylon membrane. Hybridization was performed with 	-32P-dCTP labeled
probes as indicated. For LEF-1 and c-myc, the full-length cDNAs were labeled; for Id2, keratin 8, and keratin 18, probes were generated by RT-PCR. For
normalization, membranes were stripped and reprobed with a commercially available GADPH probe.
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droperoxide (tBh), a known inducer of oxidative stress (Macip been engineered by homologous recombination to contain ei-
ther the wild-type or mutant -catenin allele (Sekine et al., 2002;et al., 2003), and analyzed the apoptotic response. At each
concentration of tBh analyzed, there was a statistically signifi- Chan et al., 2002). RT-PCR analysis revealed expression of
canonical Wnt ligands, including the highly transforming Wnt-3acant increase in the level of apoptosis in the presence of FRP1
or DKK1 overexpression (Figure 4B, left panel). Similar experi- in HCT116 cells (Figure 5A). Moreover, the wt allele-containing
clone retained high levels of uncomplexed -catenin, indicatingments performed with AB589 cells expressing FRP1 or DKK1
revealed no detectable differences in their apoptotic responses constitutive upregulation of the Wnt pathway independent of
the presence of the mutant -catenin allele (Figure 5B). Similarcompared to the vector infected cells (Figure 4B, right panel).
We noted that levels of expression of these antagonists de- results were observed with other wt -catenin allele-containing
clones (data not shown). Whereas FRP1 expression had little ifcreased with passage of the transfected and marker selected
tumor cells. This made it difficult to study their effects on tumor any effect on uncomplexed -catenin levels in the clone con-
taining only the mutant allele, there was a dramatic reductionformation in vivo and suggested a negative selective pressure
in tissue culture against these antagonists in Wnt autocrine in -catenin levels in the wild-type -catenin allele-containing
clone (Figure 5B). These findings established that an autocrinetumor cells.
Alterations in the expression of a number of genes identified Wnt loop must exist in HCT116 cells.
We next assessed the effects of FRP1 inhibition on theas targets of canonical Wnt signaling have been reported, al-
though it should be noted that there is variability among Wnt expression of Id2, Cyclin D1, and Myc, known targets of Wnt/
-catenin in colorectal cancer (Rockman et al., 2001; Tetsutarget genes in different cell systems (Giles et al., 2003). To
investigate the effects of FRP1 and DKK1 inhibition on gene and McCormick, 1999; He et al., 1998). Northern blot analysis
revealed high levels of Id2 expression in parental HCT116 as wellexpression in MDAMB157 breast tumor cells, we performed
Northern blot analysis of representative Wnt transcriptional tar- as in the -catenin mutant allele clone. The wild-type -catenin
allele-containing clone also showed Id2 expression at a some-gets, including myc (He et al., 1998), the LEF-1 transcription
factor (Filali et al., 2002), and the dominant negative helix-loop- what lower level, consistent with the relative levels of uncom-
plexed -catenin observed in these clones (Figures 5B and 5C).helix transcriptional regulator, Id2 (Rockman et al., 2001). Of
note, the expression of each was reduced by stable expression Of note, FRP1 expression led to reduction in the Id2 transcript
level in the wild-type -catenin but not in the mutant allele-of FRP1 or DKK1 (Figure 4C). We did not observe significant
changes in the levels of another Wnt target gene, cyclin D1 containing clone. Similarly, expression of Cyclin D1 and Myc in
the wild-type allele-containing clone was dramatically inhibited(Tetsu and McCormick, 1999; Shtutman et al., 1999) under the
same conditions (data not shown). However, it should be noted by FRP1 expression (Figure 5D). These results were consistent
with the ability of FRP1 to inhibit TCF-dependent reporter activ-that Wnt can induce mammary tumors in the mouse in a cyclin
D1-null genetic background, implying that in this tissue at least, ity in the -catenin wild-type allele clone (Figure 5E). To assess
the effects of Wnt autocrine inhibition in vivo, we performedcyclin D1 is unlikely to be a critical Wnt target (Yu et al., 2001;
Rowlands et al., 2003). tumorigenicity experiments utilizing parental or -catenin wild-
type allele-containing HCT116 cell lines, in which we were ableSince canonical Wnt signaling appears to be involved in
maintaining epithelial progenitor cells of several tissues (van de to obtain stable marker selected mass cultures expressing
FRP1. Of note, while FRP1 expression had no effect on tumorWetering et al., 2002b; Alonso and Fuchs, 2003; Reya et al.,
2003; Polesskaya et al., 2003), including the mouse mammary growth induced by parental cells, it caused a striking reduction in
the tumor forming ability of -catenin wild-type allele-containinggland (Li et al., 2003; Liu et al., 2004), we also investigated
whether downregulation of Wnt signaling in MDAMB157 tumor cells (Figure 5F). All of these findings establish that autocrine
Wnt signaling can be present in human colon carcinoma cellscells affected their differentiated state. RNA blot analysis with
probes for keratins 8 and 18, two markers known to be ex- that harbor downstream lesions within the canonical pathway.
pressed by differentiated mammary epithelial cells (Stingl et al.,
2001; Going, 2003), revealed that stable expression of FRP1 or Discussion
DKK1 led to a striking increase in the expression of keratin 8
as well as an increase in keratin 18 levels (Figure 4D). All of Our present studies establish constitutive upregulation of
-catenin in human tumor cells by a novel mechanism involvingthese findings provide evidence for a Wnt autocrine trans-
forming mechanism in human tumor cells. Wnt autocrine signaling. This mechanism was initially discov-
ered in the mouse mammary tumor model in which MMTV pro-
moter insertion oncogenically activates Wnt expression (NusseEffects of Wnt antagonists on HCT116 colon
cancer cells with knockout of either wild-type and Varmus, 1992). Later studies identified mutations in down-
stream components resulting in upregulation of this pathway inor mutant -catenin
Physiological Wnt signaling appears to be required for mainte- human colon carcinomas and a variety of other tumors (Polakis,
2000; Giles et al., 2003). We observed several human breastnance of the crypt progenitor phenotype in colonic epithelium
(Pinto et al., 2003; Kuhnert et al., 2004). Recent findings that and ovarian tumor cell lines, which exhibited Wnt ligand expres-
sion and increased levels of the transcriptionally active form ofFRP1 is mutated or methylated in a high fraction of colon carci-
nomas (Suzuki et al., 2002; Caldwell et al., 2004) led us to unphosphorylated, uncomplexed -catenin without detectable
lesions in commonly implicated downstream signaling compo-investigate whether a contribution of Wnt autocrine signaling in
such tumors might be masked by mutations in downstream nents, APC or -catenin. Findings that FRP1 and DKK1, two
specific antagonists of Wnt signaling at the level of ligand/recep-components of this pathway. For this purpose, we took advan-
tage of the HCT116 colorectal cancer cell line, which harbors tor interactions (Leyns et al., 1997; Wang et al., 1997; Mao et
al., 2001, 2002; Bafico et al., 2001), caused downregulationa -catenin mutation (Morin et al., 1997). HCT116 clones have
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Figure 5. Wnt autocrine signaling in HCT116 hu-
man colon cancer cells
A: RT-PCR analysis of expression of Wnt ligands in
HCT116 colorectal cancer cells. RNA was reverse
transcribed and amplified with primers specific
for each indicated Wnt as described in the Ex-
perimental Procedures. PCR product were re-
solved on 2% agarose gel and visualized by
ethidium bromide staining.
B: Effects of FRP1 on uncomplexed -catenin
levels in HCT116 parental and allele-targeted
clones. HCT116 parental and clones express-
ing either wt or mutant -catenin allele were
transfected with FRP1-HA and subjected to the
GST-E-cadherin binding assay. Uncomplexed
-catenin was detected with anti--catenin anti-
body (upper panel). The levels of FRP1 in the
lysates were detected with an anti-HA antibody
(lower panels).
C: Effects of FRP1 on the Id2 target gene expres-
sion. Top: Northern blot analysis of Id2. RNA was
extracted from HCT116 parental, and either wt
or mutant -catenin allele-containing clones
transfected with either vector control or FRP1-
HA. 40 g of total RNA was resolved on a 1%
agarose gel, transferred to a nylon membrane,
and hybridized with a RT-PCR-generated Id2
probe labeled with 32P	-dCTP (see Experimental
Proceduress and legend to Figure 4C). 28S ribo-
somal RNA was utilized as loading control. Bot-
tom: Analysis of uncomplexed -catenin and
FRP1 levels. As controls for FRP1 function, cell
lysates were obtained at the same time as the
RNA extraction and analyzed as in B.
D: FRP1 inhibits Cyclin D1 and Myc gene expres-
sion in the wild-type allele-containing HCT116
clone. Hybridization was performed utilizing
32P	-dCTP-labeled cDNAs for either Cyclin D1 or
c-myc. For normalization, membranes were
stripped and hybridized with a GADPH probe.
E: Effects of FRP1 on TCF-reporter transcriptional
activity in the wild-type allele-containing HCT116 clone. Cells were transfected and analyzed as described in the Experimental Procedures and in the
legend to Figure 2E. The ratio of the reporter activity obtained with the wild-type TOP-Glow plasmid to the activity observed with the mutant FOP-Glow
plasmid is shown.
F: FRP effects on tumor formation. The indicated cell lines were subcutaneously injected into nude mice at 2.5  106 per site. Tumor size was monitored
weekly, and values represent the mean (SD) of 4 inoculation sites per cell line.
of uncomplexed -catenin levels in these tumor cells strongly and Gamallo, 1998; Sagae et al., 1999; Wu et al., 2001). Our
present studies identified autocrine Wnt signaling, as definedimplicated an autocrine Wnt loop. Independent evidence in sup-
port of this conclusion derived from the use of siRNAs directed by the ability of the Wnt antagonists FRP1 and/or DKK1 to
cause downregulation of activated -catenin, in around 25% ofagainst LRP5 and LRP6. These studies established in PAI ovar-
ian cancer cells that LRP6 was specifically responsible for trans- human breast and ovarian cancer cell lines analyzed, implicating
this mechanism in a significant fraction of such tumors. Whetherducing the Wnt autocrine signal. Moreover, functional studies
with a human breast tumor cell line revealed that Wnt antago- autocrine Wnt signaling in these tumor cells results from Wnt
misexpression, aberrant upregulation of some other compo-nists inhibited known Wnt-induced biological effects as well as
Wnt target gene expression. All of these findings imply that nents such as a specific coreceptor not normally present, or
downregulation of Wnt antagonists remains to be elucidated.autocrine Wnt signaling plays a role in the etiology of some
human tumors. Recent evidence that FRP genes are frequently hypermeth-
ylated in colon carcinomas (Suzuki et al., 2002; Caldwell et al.,Previous studies have detected Wnt transcript expression
in human breast tumors (Huguet et al., 1994; Dale et al., 1996; 2004) suggested the possibility that autocrine Wnt signaling
might also play a role in the development of tumors which exhibitBui et al., 1997). There has also been at least one report of
cytoplasmic/nuclear staining of -catenin in breast cancer tis- constitutive pathway activation due to mutations in downstream
components. We showed that HCT116 tumor cells, harboringsues (Lin et al., 2000), whereas mutations in downstream com-
ponents of the canonical pathway have not been reported both a -catenin mutation (Morin et al., 1997) and FRP hyper-
methylation (Suzuki et al., 2002; Chan et al., 2002), expressed(Brown, 2001; Giles et al., 2003). -catenin mutations have been
observed in ovarian carcinomas of the endometroid type, which Wnt ligands. Moreover, upregulated -catenin levels observed
in HCT116 clones with targeted inactivation of the mutant allelereflects around 10%–20% of ovarian malignancies (Palacios
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Experimental procedures(Sekine et al., 2002) were specifically downregulated by exoge-
nous FRP. Finally, inhibition of Wnt autocrine signaling in wt
Constructsallele-containing HCT116 cells led to decreased expression of
Human FRP1 (Bafico et al., 1999) and DKK1 (Bafico et al., 2001) cDNAs
Wnt transcriptional targets expressed in colon carcinoma cells were subcloned into a pBabe-derived retrovirus vector containing a carboxy-
with constitutive activation of the canonical pathway (He et al., terminal HA tag and were cotransfected with the pCL-ampho packaging
plasmid into 293T cells. Culture fluids were harvested at 72 hr and titrated on1998; Rockman et al., 2001; Tetsu and McCormick, 1999).
NIH3T3 cells. The -catenin cDNA, generously provided by Dr. W. BirchmeierThese findings establish the presence of a Wnt autocrine loop
(Hulsken et al., 1994), was expressed under the control of a Tet regulatablein HCT116 cells and may help to explain why small molecule
promoter using a system we have previously reported (Sugrue et al., 1997).
antagonists of the oncogenic TCF/-catenin complex were simi- pCMV-LRP6-Flag has been previously described (Liu et al., 2003). Human
larly potent in growth inhibition of wt and mutant allele-con- LRP5, generously provided by Dr. Matthew Warman (Case Western Reserve
taining HCT116 clones (Lepourcelet et al., 2004). University), was subcloned into pcDNA3.1 (Invitrogen).
Accumulating evidence indicates that Wnt signaling is in-
Cell culture and gene transductionvolved in the self-renewal of intestinal epithelial stem/progeni-
Human tumor cell lines including breast (MDAMB157, BC3, MCF7, MDAMB231,tors as well as several other progenitor cell types (van de Weter-
MDAMB134, MDAMB175, MDAMB435, MDAMB453, MDAMB361,
ing et al., 2002b; Reya et al., 2003; Alonso and Fuchs, 2003). For MDAMB415, and MDAMB468), ovarian (A1847, A2780, PAI, SKOV3, OVCAR3,
example, DKK1 overexpression caused impaired differentiation 44S, 53S, 26S, and OV90) and colon HCT116 were maintained in Dulbecco’s
and architectural degeneration of mouse intestinal epithelium modified Eagle’s (DMEM) medium supplemented with 10% fetal bovine
serum. The immortalized mammary epithelial cell line AB589 (Stampfer and(Pinto et al., 2003; Kuhnert et al., 2004). Conversely, upregulated
Bartley, 1985) was cultured in the same media with the addition of 1 MWnt signaling can confer an immortalized stem/progenitor phe-
dexamethasone. HCT116 allele-targeted clones engineered by homologousnotype, as demonstrated by findings that expression of a domi-
recombination have been described (Sekine et al., 2002) and were main-
nant negative TCF4 in certain colorectal cancer lines induced tained in DMEM containing 2 g/ml puromycin. NIH3T3 cells were main-
a colon epithelial differentiation program (van de Wetering et tained in DMEM medium supplemented with 10% calf serum. For retroviral
al., 2002b). While this manuscript was in preparation, Suzuki et mediated gene transduction, cultures were plated at 5  105 cells per 60
mm plate in growth media containing 2 g/ml of polybrene. Twenty-foural. (2004) reported the presence of FRP hypermethylation in
hours later, cells were infected with vector control, FRP1, or DKK1 pos-colorectal adenomas as well as in earlier lesions, monoclonal
sessing either a puromycin or geneticin marker. Cells were selected for twoaberrant crypt foci (ACF), which usually lack APC mutations
weeks by addition of puromycin (0.5–2 g/ml) or geneticin (750 g/ml) to
(Siu et al., 1999). Taken together with these results, our findings the growth media. In some cases, subconfluent cultures were transfected
are consistent with the concept that Wnt autocrine activation using Fugene (Roche) according to the manufacturer’s instructions.
may be an early event that expands a colon crypt progenitor
RT-PCRpopulation and sets the stage for subsequent -catenin or APC
Total RNAs were extracted using Triazol (Invitrogen) and were reverse tran-lesions. Whereas we observed that FRP like DKK had little or
scribed using the Superscript II Reverse Trancriptase (Invitrogen). 10 l of ano effect on Wnt signaling activation induced by either overex-
100l cDNA reaction was utilized as template for amplification with the following
pressed or mutated -catenin, these authors reported that ex- primers specific for each Wnt. For human Wnt-2 forward: 5
-TGGCTC
ogenous FRP attenuated Wnt signaling in colon tumor cells with CCTCTGCTCTTGACC-3
, and reverse: 5
-AGTCAATGTTATCACTGCAGC-3
;





; for human Wnt-3a for-to be resolved.
ward: 5
-GGATACTTCTTACTCCTCTGCAG, and reverse: 5
-AATGGCGTGAn autocrine transformation mechanism was initially identi-
GACAAAGGCCGACT. Expression of other Wnt family members was ana-fied through the discovery that the sis retroviral oncogene en-
lyzed utilizing the Human WNT gene family multigene-12 RT-PCR profiling
coded platelet-derived growth factor (PDGF) (Doolittle et al., kit (SuperArray).
1983; Waterfield et al., 1983), and subsequent findings have
implicated this mechanism in naturally occurring human cancers GST-E-cadherin binding assay and immunoblot analysis
The GST-E-cadherin binding assay has been previously described (Bafico(Bafico and Aaronson, 2003; Blume-Jensen and Hunter, 2001).
et al., 1998). Uncomplexed -catenin present in 1 mg of total cell lysateIt is known that activation of receptor tyrosine kinases by growth
was subjected to SDS-PAGE and detected using a monoclonal antibodyfactors can occur within the secretory pathway. Whether signal-
to -catenin (Transduction Laboratories). Unphosphorylated -catenin was
ing is functional by a so-called intracrine mechanism within the detected with a monoclonal antibody specific for -catenin dephosphory-
secretory pathway is not resolved (Huang et al., 1984; Keating lated at residues 27–37 (Alexis). FRP1-HA and DKK1-HA were detected with
and Williams, 1988; Bejcek et al., 1989; Lee and Donoghue, an anti-HA monoclonal antibody (Hybridoma Center, Mount Sinai School of
Medicine, New York).1992; Wiley et al., 1998). In Wnt autocrine tumor cells, we dem-
onstrated that soluble DKK1 caused a striking reduction in
Apoptosis assayupregulated uncomplexed -catenin to essentially undetectable
Subconfluent cultures were treated with increasing amounts of tert-butyllevels, analogous to effects observed with Wnt transformed
hydroperoxide (tBH) for 2 hr. Twenty-four hours later, cells were washed in
mouse cells. Since soluble DKK1 acts only at the cell surface, PBS, trypsinized, and incubated with Annexin and PI using the Annexin-V-
these findings exclude an intracrine component for Wnt auto- Fluos Staining kit (Roche). Fluorescent stained cells were subjected to FACS
(Beckton Dickinson FACScan) using Cell Quest 3.2 software (Beckton Dickin-crine signaling. An increasing number of cancer agents have
son) for acquisition and analysis.successfully targeted ligands or receptors at the cell surface
(Hudziak et al., 1989; Myers et al., 1992; Slamon et al., 2001).
Luciferase reporter assaysThus, autocrine Wnt signaling could provide a novel target for
Cells plated at 3  105 per well in 6-well plates were cotransfected with 1
therapeutic intervention with DKK1 and FRP1 antagonists or g of either the TOP-glow or FOP-glow plasmids (Upstate Biotechnology)
other modalities, aimed at interfering with cell surface interac- and 0.001 g of the Renilla control plasmid (pRL-CMV) utilizing Fugene
(Roche) according to the manufacturer’s instructions. After 48 hr, cells weretions involving Wnts and their receptors.
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ties and transforming potential of human Wnt-2 are similar to Wnt-1. Onco-lysed and analyzed utilizing the Dual Luciferase Reporter Assay system
gene 7, 153–161.(Promega).
Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Nature
RNA interference 411, 355–365.
siRNAs were constructed in the pSuper expression vector as previously
Brown, A.M. (2001). Wnt signaling in breast cancer: Have we come fulldescribed (Brummelkamp et al., 2002). The 19-nucleotide target sequence
circle? Breast Cancer Res. 3, 351–355.for LRP6 was 5
-CCGCATGGTGATTGATGAA-3
, and for LRP5 was 5
-CAT
GATCGAGTCGTCCAAC-3
. 293 T or PAI cells were transiently transfected Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for stable
using Fugene (Roche) and analyzed after 72 hr. expression of short interfering RNAs in mammalian cells. Science 296, 550–
553.
Northern blot analysis
Bui, T.D., Rankin, J., Smith, K., Huguet, E.L., Ruben, S., Strachan, T., Harris,RNAs were extracted using Triazol (Invitrogen), separated by agarose gel
A.L., and Lindsay, S. (1997). A novel human Wnt gene, WNT10B, mapselectrophoresis, and transferred to a nylon membrane (Hybond, Pharmacia).
to 12q13 and is expressed in human breast carcinomas. Oncogene 14,Probes were labeled by the Random Prime Labeling System method (Amer-
1249–1253.sham Biosciences), and hybridization was performed overnight utilizing the
Hybrisol I solution (Serologicals Corporation) according to the manufactur- Cadigan, K.M., and Nusse, R. (1997). Wnt signaling: A common theme in
er’s instructions. Normalization was performed utilizing a commercial human animal development. Genes Dev. 11, 3286–3305.
GADPH control probe (BD Biosciences Clontech).
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